<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,BoldItalic" color="#000000"/>
	<fontspec id="font8" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font9" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font12" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font15" size="9" family="Symbol" color="#000000"/>
	<fontspec id="font16" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="311" width="62" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="375" width="181" height="7" font="font3" id="p1_t3" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/7/4/R455</text>
<text top="735" left="569" width="19" height="8" font="font4" id="p1_t4" reading_order_no="126" segment_no="22" tag_type="text">R455</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t5" reading_order_no="4" segment_no="2" tag_type="title">Vol 7 No 4</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="56" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title"><i><b>CYP17 </b></i></text>
<text top="102" left="112" width="54" height="14" font="font8" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title"><b>5'-UTR </b></text>
<text top="102" left="167" width="33" height="14" font="font7" id="p1_t9" reading_order_no="7" segment_no="3" tag_type="title"><i><b>Msp</b></i></text>
<text top="102" left="200" width="253" height="14" font="font8" id="p1_t10" reading_order_no="8" segment_no="3" tag_type="title"><b>A1 polymorphism and the risk of </b></text>
<text top="120" left="57" width="468" height="14" font="font8" id="p1_t11" reading_order_no="9" segment_no="3" tag_type="title"><b>premenopausal breast cancer in a German population-based </b></text>
<text top="138" left="57" width="144" height="14" font="font8" id="p1_t12" reading_order_no="10" segment_no="3" tag_type="title"><b>case–control study</b></text>
<text top="156" left="57" width="111" height="11" font="font9" id="p1_t13" reading_order_no="11" segment_no="4" tag_type="text">Emaculate Verla-Tebit</text>
<text top="155" left="168" width="5" height="8" font="font3" id="p1_t14" reading_order_no="12" segment_no="4" tag_type="text">1</text>
<text top="156" left="173" width="108" height="11" font="font9" id="p1_t15" reading_order_no="13" segment_no="4" tag_type="text">, Shan Wang-Gohrke</text>
<text top="155" left="281" width="5" height="8" font="font3" id="p1_t16" reading_order_no="14" segment_no="4" tag_type="text">2</text>
<text top="156" left="286" width="132" height="11" font="font9" id="p1_t17" reading_order_no="15" segment_no="4" tag_type="text"> and Jenny Chang-Claude</text>
<text top="155" left="418" width="5" height="8" font="font3" id="p1_t18" reading_order_no="16" segment_no="4" tag_type="text">1</text>
<text top="189" left="57" width="3" height="5" font="font10" id="p1_t19" reading_order_no="17" segment_no="5" tag_type="text">1</text>
<text top="189" left="60" width="436" height="7" font="font3" id="p1_t20" reading_order_no="18" segment_no="5" tag_type="text">Division of Clinical Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum), Heidelberg, Germany</text>
<text top="198" left="57" width="3" height="5" font="font10" id="p1_t21" reading_order_no="19" segment_no="5" tag_type="text">2</text>
<text top="199" left="60" width="361" height="7" font="font3" id="p1_t22" reading_order_no="20" segment_no="5" tag_type="text">Molecular Biology Laboratory, Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany</text>
<text top="217" left="57" width="451" height="7" font="font3" id="p1_t23" reading_order_no="21" segment_no="6" tag_type="text">Corresponding author: Shan Wang-Gohrke, shan.wang@medizin.uni-ulm.deJenny Chang-Claude, j.chang-claude@dkfz-heidelberg.de</text>
<text top="235" left="57" width="495" height="7" font="font3" id="p1_t24" reading_order_no="22" segment_no="7" tag_type="text">Received: 13 Dec 2004 Revisions requested: 31 Jan 2005 Revisions received: 14 Feb 2005 Accepted: 18 Mar 2005 Published: 12 Apr 2005</text>
<text top="253" left="57" width="85" height="7" font="font11" id="p1_t25" reading_order_no="23" segment_no="8" tag_type="text"><i>Breast Cancer Research</i></text>
<text top="253" left="141" width="25" height="7" font="font3" id="p1_t26" reading_order_no="24" segment_no="8" tag_type="text"> 2005, </text>
<text top="253" left="166" width="4" height="7" font="font2" id="p1_t27" reading_order_no="25" segment_no="8" tag_type="text"><b>7</b></text>
<text top="253" left="171" width="129" height="7" font="font3" id="p1_t28" reading_order_no="26" segment_no="8" tag_type="text">:R455-R464 (DOI 10.1186/bcr1027)</text>
<text top="263" left="57" width="260" height="7" font="font3" id="p1_t29" reading_order_no="27" segment_no="9" tag_type="text"><a href="http://breast-cancer-research.com/content/7/4/R455">This article is online at: http://breast-cancer-research.com/content/7/4/R455</a></text>
<text top="273" left="57" width="66" height="7" font="font3" id="p1_t30" reading_order_no="28" segment_no="10" tag_type="text">© 2005 Verla-Tebit</text>
<text top="273" left="123" width="17" height="7" font="font11" id="p1_t31" reading_order_no="29" segment_no="10" tag_type="text"><i> et al</i></text>
<text top="273" left="140" width="107" height="7" font="font3" id="p1_t32" reading_order_no="30" segment_no="10" tag_type="text">.; licensee BioMed Central Ltd. </text>
<text top="283" left="57" width="495" height="7" font="font3" id="p1_t33" reading_order_no="31" segment_no="11" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/</a></text>
<text top="293" left="57" width="426" height="7" font="font3" id="p1_t34" reading_order_no="32" segment_no="11" tag_type="text"><a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="323" left="57" width="43" height="10" font="font12" id="p1_t35" reading_order_no="33" segment_no="12" tag_type="title"><b>Abstract</b></text>
<text top="343" left="57" width="49" height="8" font="font13" id="p1_t36" reading_order_no="34" segment_no="13" tag_type="text"><b>Introduction</b></text>
<text top="343" left="106" width="191" height="8" font="font14" id="p1_t37" reading_order_no="35" segment_no="13" tag_type="text"> Studies on the association between the</text>
<text top="354" left="57" width="85" height="8" font="font14" id="p1_t38" reading_order_no="36" segment_no="13" tag_type="text">cytochrome P450c17</text>
<text top="351" left="142" width="6" height="12" font="font15" id="p1_t39" reading_order_no="37" segment_no="13" tag_type="text">α</text>
<text top="354" left="148" width="30" height="8" font="font14" id="p1_t40" reading_order_no="38" segment_no="13" tag_type="text"> gene (</text>
<text top="354" left="177" width="28" height="8" font="font16" id="p1_t41" reading_order_no="39" segment_no="13" tag_type="text"><i>CYP17</i></text>
<text top="354" left="206" width="91" height="8" font="font14" id="p1_t42" reading_order_no="40" segment_no="13" tag_type="text">) 5'-untranslated region</text>
<text top="364" left="57" width="17" height="8" font="font16" id="p1_t43" reading_order_no="41" segment_no="13" tag_type="text"><i>Msp</i></text>
<text top="364" left="73" width="224" height="8" font="font14" id="p1_t44" reading_order_no="42" segment_no="13" tag_type="text">A1 genetic polymorphism and breast cancer risk have</text>
<text top="375" left="57" width="240" height="8" font="font14" id="p1_t45" reading_order_no="43" segment_no="13" tag_type="text">yielded inconsistent results. Higher levels of estrogen have been</text>
<text top="385" left="57" width="240" height="8" font="font14" id="p1_t46" reading_order_no="44" segment_no="13" tag_type="text">reported among young nulliparous women with the A2 allele.</text>
<text top="396" left="57" width="143" height="8" font="font14" id="p1_t47" reading_order_no="45" segment_no="13" tag_type="text">Therefore we assessed the impact of </text>
<text top="396" left="200" width="31" height="8" font="font16" id="p1_t48" reading_order_no="46" segment_no="13" tag_type="text"><i>CYP17 </i></text>
<text top="396" left="231" width="66" height="8" font="font14" id="p1_t49" reading_order_no="47" segment_no="13" tag_type="text">genotypes on the</text>
<text top="406" left="57" width="235" height="8" font="font14" id="p1_t50" reading_order_no="48" segment_no="13" tag_type="text">risk of premenopausal breast cancer, with emphasis on parity.</text>
<text top="427" left="57" width="36" height="8" font="font13" id="p1_t51" reading_order_no="49" segment_no="15" tag_type="text"><b>Methods</b></text>
<text top="427" left="92" width="205" height="8" font="font14" id="p1_t52" reading_order_no="50" segment_no="15" tag_type="text"> We used data from a population-based case–control</text>
<text top="438" left="57" width="240" height="8" font="font14" id="p1_t53" reading_order_no="51" segment_no="15" tag_type="text">study of women aged below 51 years conducted from 1992 to</text>
<text top="448" left="57" width="240" height="8" font="font14" id="p1_t54" reading_order_no="52" segment_no="15" tag_type="text">1995 in Germany. Analyses were restricted to clearly</text>
<text top="459" left="57" width="212" height="8" font="font14" id="p1_t55" reading_order_no="53" segment_no="15" tag_type="text">premenopausal women with complete information on </text>
<text top="459" left="269" width="28" height="8" font="font16" id="p1_t56" reading_order_no="54" segment_no="15" tag_type="text"><i>CYP17</i></text>
<text top="469" left="57" width="240" height="8" font="font14" id="p1_t57" reading_order_no="55" segment_no="15" tag_type="text">and encompassed 527 case subjects and 904 controls, 99.5%</text>
<text top="480" left="57" width="157" height="8" font="font14" id="p1_t58" reading_order_no="56" segment_no="15" tag_type="text">of whom were of European descent. The </text>
<text top="480" left="214" width="17" height="8" font="font16" id="p1_t59" reading_order_no="57" segment_no="15" tag_type="text"><i>Msp</i></text>
<text top="480" left="231" width="67" height="8" font="font14" id="p1_t60" reading_order_no="58" segment_no="15" tag_type="text">A1 polymorphism</text>
<text top="490" left="57" width="240" height="8" font="font14" id="p1_t61" reading_order_no="59" segment_no="15" tag_type="text">was analyzed using PCR-RFLP (PCR–restriction fragment</text>
<text top="501" left="57" width="108" height="8" font="font14" id="p1_t62" reading_order_no="60" segment_no="15" tag_type="text">length polymorphism) assay.</text>
<text top="522" left="57" width="31" height="8" font="font13" id="p1_t63" reading_order_no="61" segment_no="17" tag_type="text"><b>Results</b></text>
<text top="522" left="87" width="210" height="8" font="font14" id="p1_t64" reading_order_no="62" segment_no="17" tag_type="text"> The frequencies of the variant allele among the cases</text>
<text top="532" left="57" width="212" height="8" font="font14" id="p1_t65" reading_order_no="63" segment_no="17" tag_type="text">and controls were 43% and 41%, respectively. Overall, </text>
<text top="532" left="269" width="28" height="8" font="font16" id="p1_t66" reading_order_no="64" segment_no="17" tag_type="text"><i>CYP17</i></text>
<text top="343" left="315" width="240" height="8" font="font14" id="p1_t67" reading_order_no="65" segment_no="14" tag_type="text">A1/A2 and A2/A2 genotypes compared with the A1/A1</text>
<text top="354" left="315" width="240" height="8" font="font14" id="p1_t68" reading_order_no="66" segment_no="14" tag_type="text">genotype were not associated with breast cancer, with adjusted</text>
<text top="364" left="315" width="240" height="8" font="font14" id="p1_t69" reading_order_no="67" segment_no="14" tag_type="text">odds ratios (ORs) of 1.04 and 1.23, respectively. Among</text>
<text top="375" left="315" width="241" height="8" font="font14" id="p1_t70" reading_order_no="68" segment_no="14" tag_type="text">nulliparous women, however, breast cancer risk was elevated for</text>
<text top="385" left="315" width="240" height="8" font="font14" id="p1_t71" reading_order_no="69" segment_no="14" tag_type="text">the A1/A2 (OR = 1.31; 95% confidence interval (CI) 0.74 to</text>
<text top="396" left="315" width="240" height="8" font="font14" id="p1_t72" reading_order_no="70" segment_no="14" tag_type="text">2.32) and the A2/A2 genotype (OR = 2.12; 95% CI 1.04 to</text>
<text top="406" left="315" width="240" height="8" font="font14" id="p1_t73" reading_order_no="71" segment_no="14" tag_type="text">4.32) compared with the A1/A1 genotype, with a trend towards</text>
<text top="417" left="315" width="201" height="8" font="font14" id="p1_t74" reading_order_no="72" segment_no="14" tag_type="text">increasing risk associated with number of A2 alleles (</text>
<text top="417" left="517" width="8" height="8" font="font16" id="p1_t75" reading_order_no="73" segment_no="14" tag_type="text"><i>P </i></text>
<text top="417" left="525" width="31" height="8" font="font14" id="p1_t76" reading_order_no="74" segment_no="14" tag_type="text">= 0.04).</text>
<text top="427" left="315" width="60" height="8" font="font14" id="p1_t77" reading_order_no="75" segment_no="14" tag_type="text">Otherwise, the </text>
<text top="427" left="375" width="31" height="8" font="font16" id="p1_t78" reading_order_no="76" segment_no="14" tag_type="text"><i>CYP17 </i></text>
<text top="427" left="407" width="149" height="8" font="font14" id="p1_t79" reading_order_no="77" segment_no="14" tag_type="text">polymorphism was found neither to be</text>
<text top="438" left="315" width="241" height="8" font="font14" id="p1_t80" reading_order_no="78" segment_no="14" tag_type="text">an effect modifier of breast cancer risks nor to be associated</text>
<text top="448" left="315" width="83" height="8" font="font14" id="p1_t81" reading_order_no="79" segment_no="14" tag_type="text">with stage of disease.</text>
<text top="490" left="315" width="46" height="8" font="font13" id="p1_t82" reading_order_no="80" segment_no="16" tag_type="text"><b>Conclusion</b></text>
<text top="490" left="361" width="195" height="8" font="font14" id="p1_t83" reading_order_no="81" segment_no="16" tag_type="text"> Our results do not indicate a major influence of</text>
<text top="501" left="315" width="50" height="8" font="font16" id="p1_t84" reading_order_no="82" segment_no="16" tag_type="text"><i>CYP17 Msp</i></text>
<text top="501" left="365" width="191" height="8" font="font14" id="p1_t85" reading_order_no="83" segment_no="16" tag_type="text">A1 polymorphism on the risk of premenopausal</text>
<text top="511" left="315" width="240" height="8" font="font14" id="p1_t86" reading_order_no="84" segment_no="16" tag_type="text">breast cancer, but suggest that it may have an impact on breast</text>
<text top="522" left="315" width="241" height="8" font="font14" id="p1_t87" reading_order_no="85" segment_no="16" tag_type="text">cancer risk among nulliparous women. The finding, however,</text>
<text top="532" left="315" width="154" height="8" font="font14" id="p1_t88" reading_order_no="86" segment_no="16" tag_type="text">needs to be confirmed in further studies.</text>
<text top="582" left="57" width="64" height="10" font="font12" id="p1_t89" reading_order_no="87" segment_no="18" tag_type="title"><b>Introduction</b></text>
<text top="593" left="57" width="240" height="9" font="font14" id="p1_t90" reading_order_no="88" segment_no="20" tag_type="text">The risk of breast cancer is related to genetic, environmental,</text>
<text top="605" left="57" width="240" height="9" font="font14" id="p1_t91" reading_order_no="89" segment_no="20" tag_type="text">and lifestyle factors that influence the level of exposure to</text>
<text top="617" left="57" width="240" height="9" font="font14" id="p1_t92" reading_order_no="90" segment_no="20" tag_type="text">estrogens and other sex hormones<a href=""> [1]. Regarding gen</a>etic fac-</text>
<text top="629" left="57" width="240" height="9" font="font14" id="p1_t93" reading_order_no="91" segment_no="20" tag_type="text">tors, high-penetrance cancer-susceptibility genes such as</text>
<text top="640" left="57" width="34" height="9" font="font16" id="p1_t94" reading_order_no="92" segment_no="20" tag_type="text"><i>BRCA1 </i></text>
<text top="640" left="90" width="17" height="9" font="font14" id="p1_t95" reading_order_no="93" segment_no="20" tag_type="text">and </text>
<text top="640" left="107" width="34" height="9" font="font16" id="p1_t96" reading_order_no="94" segment_no="20" tag_type="text"><i>BRCA2 </i></text>
<text top="640" left="141" width="156" height="9" font="font14" id="p1_t97" reading_order_no="95" segment_no="20" tag_type="text">are associated with some cases of famil-</text>
<text top="652" left="57" width="240" height="9" font="font14" id="p1_t98" reading_order_no="96" segment_no="20" tag_type="text">ial breast cancer, though this association accounts for only</text>
<text top="664" left="57" width="240" height="9" font="font14" id="p1_t99" reading_order_no="97" segment_no="20" tag_type="text">about 5% of all breast cancer cases [<a href="">2]</a>, while low-penetrance</text>
<text top="676" left="57" width="240" height="9" font="font14" id="p1_t100" reading_order_no="98" segment_no="20" tag_type="text">genes together with endogenous and lifestyle factors are likely</text>
<text top="687" left="57" width="240" height="9" font="font14" id="p1_t101" reading_order_no="99" segment_no="20" tag_type="text">to account for a higher proportion of breast canc<a href="">er cases [3].</a></text>
<text top="699" left="57" width="240" height="9" font="font14" id="p1_t102" reading_order_no="100" segment_no="20" tag_type="text">These low-penetrance genes include genes involved in the</text>
<text top="582" left="315" width="184" height="9" font="font14" id="p1_t103" reading_order_no="101" segment_no="19" tag_type="text">metabolism of sex hormones. One such gene is </text>
<text top="582" left="499" width="29" height="9" font="font16" id="p1_t104" reading_order_no="102" segment_no="19" tag_type="text"><i>CYP17</i></text>
<text top="582" left="529" width="27" height="9" font="font14" id="p1_t105" reading_order_no="103" segment_no="19" tag_type="text">, which</text>
<text top="593" left="315" width="172" height="9" font="font14" id="p1_t106" reading_order_no="104" segment_no="19" tag_type="text">codes for the enzyme cytochrome P450c17</text>
<text top="591" left="487" width="6" height="12" font="font15" id="p1_t107" reading_order_no="105" segment_no="19" tag_type="text">α</text>
<text top="593" left="493" width="63" height="9" font="font14" id="p1_t108" reading_order_no="106" segment_no="19" tag_type="text">, responsible for</text>
<text top="605" left="315" width="82" height="9" font="font14" id="p1_t109" reading_order_no="107" segment_no="19" tag_type="text">catalyzing steroid 17</text>
<text top="602" left="398" width="6" height="12" font="font15" id="p1_t110" reading_order_no="108" segment_no="19" tag_type="text">α</text>
<text top="605" left="404" width="152" height="9" font="font14" id="p1_t111" reading_order_no="109" segment_no="19" tag_type="text">-hydroxylase and 17,20-lyase activities</text>
<text top="617" left="315" width="240" height="9" font="font14" id="p1_t112" reading_order_no="110" segment_no="19" tag_type="text">at key branch points in the estrogen biosynthesis pathway <a href="">[4].</a></text>
<text top="629" left="315" width="240" height="9" font="font14" id="p1_t113" reading_order_no="111" segment_no="19" tag_type="text">An increase or decrease in activity of these enzymes may alter</text>
<text top="640" left="315" width="240" height="9" font="font14" id="p1_t114" reading_order_no="112" segment_no="19" tag_type="text">the level of endogenous estrogen (estradiol), thereby influenc-</text>
<text top="652" left="315" width="240" height="9" font="font14" id="p1_t115" reading_order_no="113" segment_no="19" tag_type="text">ing susceptibility to breast canc<a href="">er [5,6]. </a>One of the polymor-</text>
<text top="664" left="315" width="61" height="9" font="font14" id="p1_t116" reading_order_no="114" segment_no="19" tag_type="text">phisms of the </text>
<text top="664" left="376" width="32" height="9" font="font16" id="p1_t117" reading_order_no="115" segment_no="19" tag_type="text"><i>CYP17 </i></text>
<text top="664" left="410" width="146" height="9" font="font14" id="p1_t118" reading_order_no="116" segment_no="19" tag_type="text">gene is a thymidine substitution for</text>
<text top="676" left="315" width="141" height="9" font="font14" id="p1_t119" reading_order_no="117" segment_no="19" tag_type="text">cytosine (T to C) giving rise to an </text>
<text top="676" left="456" width="17" height="9" font="font16" id="p1_t120" reading_order_no="118" segment_no="19" tag_type="text"><i>Msp</i></text>
<text top="676" left="473" width="82" height="9" font="font14" id="p1_t121" reading_order_no="119" segment_no="19" tag_type="text">A1 restriction site at</text>
<text top="687" left="315" width="240" height="9" font="font14" id="p1_t122" reading_order_no="120" segment_no="19" tag_type="text">nucleotide 27 in the 5'-untranslated region (5'-UTR) promoter</text>
<text top="699" left="315" width="41" height="9" font="font14" id="p1_t123" reading_order_no="121" segment_no="19" tag_type="text"><a href="">[7]</a>. The </text>
<text top="699" left="357" width="17" height="9" font="font16" id="p1_t124" reading_order_no="122" segment_no="19" tag_type="text"><i>Msp</i></text>
<text top="699" left="374" width="182" height="9" font="font14" id="p1_t125" reading_order_no="123" segment_no="19" tag_type="text">A1 polymorphism has three genotypes: a</text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t126" reading_order_no="124" segment_no="21" tag_type="footnote">CI = confidence interval; OR = odds ratio; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; UTR = untranslated </text>
<text top="734" left="57" width="23" height="7" font="font3" id="p1_t127" reading_order_no="125" segment_no="21" tag_type="footnote">region.</text>
</page>
</pdf2xml>
